TMP-SMX for Non-HIV PCP: A Prospective Multicenter Study

Efficacy and Safety of TMP-SMX for Non-HIV-Related PCP: A Prospective Multicenter Observational Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07690410

Enrollment

480

Registered

2026-07-08

Start date

2026-08-01

Completion date

2029-06-30

Last updated

2026-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis Jirovecii Pneumonia in Non-HIV Patients

Keywords

Trimethoprim-Sulfamethoxazole, Prospective Studies, Multicenter Study, Pneumocystis jirovecii, Pneumonia

Brief summary

Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection in immunocompromised patients. Non-HIV-related PCP has a rising incidence, faster progression, and higher mortality than HIV-associated cases. Trimethoprim-sulfamethoxazole (TMP/SMX) is first-line, but standard dosing (TMP 15-20 mg/kg/day) is associated with adverse reaction rates of 56%-72%, and prospective evidence is scarce. This prospective, multicentre, observational study aims to compare the efficacy and safety of low-dose (TMP \<15 mg/kg/day) versus conventional-dose TMP/SMX for non-HIV-related PCP, and to explore the value of therapeutic drug monitoring in individualising therapy, without interfering with routine clinical decisions. The investigators plan to enrol 480 patients aged ≥18 years with confirmed non-HIV-related PCP receiving TMP/SMX as initial treatment, excluding those with allergy, prophylaxis, treatment \<72 hours, or supratherapeutic dosing. The primary outcome is treatment failure at day 21 (all-cause death or new invasive ventilation). Secondary outcomes include day-8 oxygenation change, 30- and 90-day mortality, regimen completion, adverse events (CTCAE v6.0), and hospital/ICU stay. Propensity score matching will be the main analysis, with inverse probability weighting for sensitivity.

Interventions

DRUGlow-dose TMP-SMX regimen

TMP \<15 mg/kg/day

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years, * Meet the diagnostic criteria for Non-HIV-associated PCP, * Receiving TMP/SMX as the initial treatment for PCP, * Provide written informed consent to participate in the study.

Exclusion criteria

* Pregnant or breastfeeding women, * History of severe allergy or documented intolerance to TMP/SMX, * TMP/SMX used for PCP prophylaxis rather than treatment, * TMP/SMX treatment duration \<72 hours at the time of screening, * TMP/SMX administered at a supratherapeutic dose (TMP component \>20 mg/kg/day).

Design outcomes

Primary

Measure	Time frame	Description
Treatment Failure at Day 21	Up to 21 days	Composite of all-cause death or new invasive mechanical ventilation (including escalation from non-invasive to invasive) within 21 days of treatment initiation.

Contacts

CONTACTYangmin Hu

zrhym@zju.edu.cn+86 057187783891

PRINCIPAL_INVESTIGATORYangmin Hu

Second Affiliated Hospital, School of Medicine, Zhejiang University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 15, 2026